New anticoagulant drugs

被引：91

作者：

Weitz, JI

Hirsh, J

Samama, MM

机构：

来源：

CHEST | 2004年 / 126卷 / 03期

关键词：

anticoagulants; antithrombotic drugs; profibrinolytic agents;

D O I：

10.1378/chest.126.3_suppl.265S

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

This article about new anticoagulant drugs is part of the seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. The limitations of existing oral and parenteral anticoagulant agents have prompted a search for novel agents. Focusing on new anticoagulant drugs for the prevention and treatment of arterial and venous thrombosis, this article (1) reviews arterial and venous thrombogenesis, (2) discusses the regulation of coagulation, (3) describes the pathways for testing new anticoagulant agents, (4) describes new anticoagulant strategies focusing primarily on agents in phase 11 or III clinical testing, and (5) provides clinical perspective as to which of these new strategies is most likely to succeed.

引用

页码：265S / 286S

页数：22

共 140 条

[1] Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study [J].

Abraham, E ;

Reinhart, K ;

Svoboda, P ;

Seibert, A ;

Olthoff, D ;

Dal Nogare, A ;

Postier, R ;

Hempelmann, G ;

Butler, T ;

Martin, E ;

Zwingelstein, C ;

Percell, S ;

Shu, V ;

Leighton, A ;

Creasey, AA .

CRITICAL CARE MEDICINE, 2001, 29 (11) :2081-2089

[2] Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis -: A randomized controlled trial [J].

Abraham, E ;

Reinhart, K ;

Opal, S ;

Demeyer, I ;

Doig, C ;

Rodriguez, AL ;

Beale, R ;

Svoboda, P ;

Laterre, PF ;

Simon, S ;

Light, B ;

Spapen, H ;

Stone, J ;

Seibert, A ;

Peckelsen, C ;

De Deyne, C ;

Postier, R ;

Pettilä, V ;

Sprung, CL ;

Artigas, A ;

Percell, SR ;

Shu, V ;

Zwingelstein, C ;

Tobias, J ;

Poole, L ;

Stolzenbach, JC ;

Creasey, AA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02) :238-247

[3] Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. [J].

Agnelli, G ;

Prandoni, P ;

Santamaria, MG ;

Bagatella, P ;

Iorio, A ;

Bazzan, M ;

Moia, M ;

Guazzaloca, G ;

Bertoldi, A ;

Tomasi, C ;

Scannapieco, G ;

Ageno, W ;

Ascani, A ;

Villalta, S ;

Frulla, M ;

Mosena, L ;

Girolami, A ;

Vaccarino, A ;

Alatri, A ;

Palareti, G ;

Marchesi, M ;

Ambrosio, GB ;

Parisi, R ;

Doria, S ;

Steidl, L ;

Ambrosini, F ;

Silingardi, M ;

Ghirarduzzi, A ;

Iori, I .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (03) :165-169

[4]

AGNELLI G, 2003, J THROMB HAEMOST S, V1

[5]

Albers GW, 2003, LANCET, V362, P1691

[6] Antithrombotic therapy in atrial fibrillation [J].

Albers, GW ;

Dalen, JE ;

Laupacis, A ;

Manning, WJ ;

Petersen, P ;

Singer, DE .

CHEST, 2001, 119 (01) :194S-206S

[7] BINDING OF FIBRINOGEN TO HUMAN-MONOCYTES [J].

ALTIERI, DC ;

MANNUCCI, PM ;

CAPITANIO, AM .

JOURNAL OF CLINICAL INVESTIGATION, 1986, 78 (04) :968-976

[8] ADHESIVE RECEPTOR MAC-1 COORDINATES THE ACTIVATION OF FACTOR-X ON STIMULATED CELLS OF MONOCYTIC AND MYELOID DIFFERENTIATION - AN ALTERNATIVE INITIATION OF THE COAGULATION PROTEASE CASCADE [J].

ALTIERI, DC ;

MORRISSEY, JH ;

EDGINGTON, TS .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (20) :7462-7466

[9] HIRUDIN IN ACUTE MYOCARDIAL-INFARCTION - SAFETY REPORT FROM THE THROMBOLYSIS AND THROMBIN INHIBITION IN MYOCARDIAL-INFARCTION (TIMI)-9A TRIAL [J].

ANTMAN, EM .

CIRCULATION, 1994, 90 (04) :1624-1630

[10] Hirudin in acute myocardial infarction - Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial [J].

Antman, EM .

CIRCULATION, 1996, 94 (05) :911-921

← 1 2 3 4 5 6 7 8 9 10 →